Streamlining EHR Integration through Common Data Models for RWE

Electronic Health Records (EHRs) provide a vast source of real-world data (RWD), but differences in formats and terminologies across systems create integration challenges. Common Data Models (CDMs) offer a solution by providing standardized data structures that enable consistent analysis across institutions, regions, and platforms.

This guide explores how pharmaceutical professionals and clinical trial stakeholders can use CDMs to harmonize EHR data, facilitating reliable real-world evidence (RWE) generation for regulatory and scientific purposes.

Why Common Data Models Are Essential:

Inconsistent EHR formats across healthcare systems hinder large-scale observational studies. CDMs solve this problem by:

• Defining standard tables and fields (e.g., patient demographics, diagnoses, drug exposures)
• Ensuring uniform terminologies (e.g., SNOMED CT, LOINC, RxNorm)
• Enabling cross-database analytics with common logic
• Supporting reproducible research through aligned metadata

Whether working on safety studies or comparative effectiveness research, CDMs improve data quality and integrity, enhancing GMP compliance when observational results are used to support regulatory filings.

Key Common Data Models Used in EHR Integration:

Here are the most widely adopted CDMs in the pharma and research community:

1. OMOP (Observational Medical Outcomes Partnership):
   • Developed by the Observational Health Data Sciences and Informatics (OHDSI) collaborative
   • Captures clinical data in a person-centric format
   • Supports standardized vocabularies and cohort definitions
2. Sentinel Common Data Model:
   • Created by the U.S. FDA’s Sentinel Initiative
   • Focused on post-marketing safety surveillance
   • Includes robust privacy protections and distributed analytics
3. PCORnet CDM:
   • Developed by the Patient-Centered Outcomes Research Institute
   • Optimized for patient-centered outcomes and engagement studies
4. HL7 FHIR (Fast Healthcare Interoperability Resources):
   • Not a CDM in the traditional sense, but a data exchange standard
   • Enables real-time EHR integration via APIs
   • Increasingly used in dynamic RWE platforms

Steps to Implement a Common Data Model for EHR Integration:

To adopt a CDM in your real-world evidence program, follow these steps:

1. Choose a CDM: Based on study goals, regulatory alignment, and partner ecosystem.
2. Extract Data: From source EHRs in both structured and unstructured formats.
3. Transform and Map: Clean and normalize data using extract-transform-load (ETL) pipelines, aligning with the CDM structure.
4. Standardize Terminologies: Use tools like Usagi for OMOP to map local codes to global standards.
5. Validate Data Quality: Perform checks on completeness, consistency, and referential integrity.
6. Deploy Analytics Tools: Utilize cohort builders, statistical engines, and visualization dashboards compatible with the CDM.

For long-term success, integrate CDM workflows into your Pharma SOP templates for reproducibility and compliance.

Regulatory Acceptance of CDM-Based Evidence:

Global regulatory bodies increasingly recognize CDM-aligned evidence in submissions. For example:

• The USFDA accepts Sentinel CDM results in drug safety monitoring.
• The EMA leverages OMOP-standardized data in DARWIN EU for RWE analysis.
• Health Canada encourages structured data submissions to improve review efficiency.

Maintaining traceability from original EHR sources to CDM tables is critical for regulatory audits. Align with data provenance principles to ensure integrity.

Common Challenges and Solutions in CDM Adoption:

• Challenge: Mapping diverse data sources with incompatible formats
• Solution: Use ETL automation tools like WhiteRabbit and RabbitInAHat (OMOP) for structured mapping
• Challenge: Clinical terminologies vary by institution or country
• Solution: Leverage SNOMED CT crosswalks and LOINC/RxNorm mappings
• Challenge: Governance and access across multi-site collaborations
• Solution: Employ federated data models or distributed queries with privacy controls

Build competency by including CDM mapping training in your Pharma Validation programs to improve internal capacity.

Case Example: OMOP CDM in Oncology RWE

In an oncology real-world evidence study, a pharmaceutical sponsor mapped EHR data from five hospitals to the OMOP CDM. They used standardized definitions to:

• Identify eligible lung cancer patients
• Track treatment regimens and outcomes
• Evaluate progression-free survival across treatment cohorts

This enabled fast data extraction and consistent outcome definitions, accelerating the generation of real-world insights aligned with StabilityStudies.in protocols.

Best Practices for Long-Term Sustainability:

• Document your ETL pipelines and update them regularly as source EHRs evolve
• Use open-source CDM tools to avoid vendor lock-in
• Join communities like OHDSI or PCORnet to stay updated on CDM advancements
• Align with pharma regulatory compliance for traceable and auditable CDM processes
• Incorporate metadata standards to improve data discoverability and reusability

CDM maturity models are emerging to guide institutions through phased adoption. Early wins in pilot projects can build momentum for wider rollouts.

Conclusion: Building RWE Infrastructure through CDMs

As the demand for high-quality real-world evidence grows, integrating EHRs using common data models becomes indispensable. CDMs provide the structure, standardization, and scalability needed to transform raw EHR data into regulatory-grade evidence.

Whether leveraging OMOP, Sentinel, PCORnet, or HL7 FHIR, success lies in methodical implementation, rigorous validation, and strategic alignment with regulatory and scientific goals. With the right approach, CDMs can unlock the full potential of EHRs for next-generation evidence generation in pharmaceuticals.

How to Link Patient Registries with EHRs for Better Real-World Data Collection

Linking patient registries with Electronic Health Records (EHRs) transforms registry studies by streamlining real-world data (RWD) collection, reducing manual entry, and improving data accuracy. This tutorial is designed to guide pharma professionals and clinical trial teams in integrating registries with EHR systems effectively. We cover the technical considerations, regulatory implications, and best practices to enable seamless data flow for powerful real-world evidence (RWE) generation.

Why Link Registries with EHRs?

EHR systems are primary sources of real-world clinical data. By linking EHRs with registries, organizations can:

• Automate patient data capture for longitudinal tracking
• Minimize transcription errors and manual burden
• Enhance data quality and completeness
• Facilitate timely updates and outcome monitoring

This integration is especially valuable for observational studies and post-marketing surveillance, aligning with GMP quality control standards for data traceability and accuracy.

Step 1: Define the Integration Goals and Scope

Begin by defining the integration’s purpose. Examples include:

• Automating baseline and follow-up data collection
• Triggering alerts for adverse events or follow-ups
• Real-time reporting of patient-reported outcomes (PROs)
• Regulatory submissions using hybrid EHR-registry data

Clearly outline which data elements will flow from the EHR and how they’ll be mapped in the registry system.

Step 2: Use Standardized Data Models and Interoperability Protocols

Interoperability is key to successful linkage. Adopt data standards and formats such as:

• HL7 FHIR (Fast Healthcare Interoperability Resources)
• CDISC for research compatibility
• LOINC, SNOMED CT, and ICD-10 coding

Standardization facilitates clean data transfers, validation, and global acceptance. You can align this with equipment qualification and computer system validation best practices.

Step 3: Build a Robust Data Mapping Strategy

Effective EHR-to-registry integration relies on structured mapping. Identify:

1. Source fields in the EHR (e.g., patient name, diagnosis, lab results)
2. Target fields in the registry database
3. Transformation rules (unit conversion, value mapping)
4. Data entry triggers (e.g., clinic visit, lab result upload)

Use data dictionaries and interface control documents to maintain transparency and auditability.

Step 4: Ensure Data Privacy, Security, and Regulatory Compliance

Integration must comply with data protection laws like GDPR, HIPAA, and local regulations. Steps include:

• Implementing encryption and access controls
• Maintaining data segregation between clinical and research data
• Ensuring electronic informed consent for data sharing
• Auditing access and activity logs

As per TGA requirements, all linked systems must maintain data integrity and traceability.

Step 5: Choose the Right Integration Architecture

There are different architectures depending on registry complexity and EHR systems:

• Point-to-point integration: Direct link between one EHR and the registry system
• Middleware/API integration: Uses interface engines or APIs for scalable multi-site linkage
• Cloud-based data hubs: Centralizes data from multiple EHRs to push into the registry

For large-scale registry studies, API-driven middleware offers flexibility and security.

Step 6: Validate and Monitor the Integration

Validation is critical before go-live. Perform:

• User acceptance testing (UAT)
• Data integrity and accuracy checks
• Automated rule testing (e.g., missing fields, format errors)
• Reconciliation of source EHR records with registry data

Maintain a registry-specific SOP validation in pharma to document and standardize these procedures.

Step 7: Train Users and Establish Governance

Train clinical, IT, and research staff on:

• How data flows between EHR and registry
• How to resolve data mismatches or alerts
• Interpreting and correcting mapping errors
• Using dashboards for monitoring data flow

Establish governance structures to handle data stewardship, change management, and system upgrades.

Step 8: Ensure Continuous Improvement and Scalability

After deployment, continue monitoring integration performance and look for enhancements:

• Expanding to additional sites or EHR platforms
• Adding new variables or outcomes
• Reducing latency between data entry and registry update
• Capturing patient-generated data via mobile apps or patient portals

Periodically reassess whether the system supports your registry’s research and Stability Studies applications for long-term data collection.

Common Challenges and How to Overcome Them:

• Data inconsistency: Use transformation rules and codebooks
• System incompatibility: Employ HL7/FHIR-based APIs
• Regulatory ambiguity: Consult early with pharma regulatory compliance experts
• User resistance: Invest in user training and feedback loops

Conclusion:

Linking registries with Electronic Health Records is not just a technical upgrade—it’s a strategic move toward smarter, faster, and more reliable real-world data capture. With the right planning, standards, and compliance framework, registry-EHR integration can significantly enhance the value and scalability of your observational research. As RWE continues to shape regulatory and clinical decisions, mastering this integration is essential for pharma and clinical professionals alike.